import { BlogPost } from '@/lib/types'

export const blogPosts: BlogPost[] = [
  {
    id: 'post-1',
    slug: 'bpc-157-mechanisms-tissue-repair',
    title: 'BPC-157: Mechanisms of Action in Tissue Repair Research',
    excerpt: "A comprehensive review of the current literature on BPC-157's proposed mechanisms in tendon, ligament, and gut tissue repair studies.",
    content: `BPC-157 (Body Protection Compound-157) is a pentadecapeptide consisting of 15 amino acids, originally isolated as a partial sequence of a cytoprotective protein found in human gastric juice. Since its identification, it has attracted sustained interest in preclinical research due to its apparent stability in physiological environments and its broad range of observed biological effects. Unlike many peptides that degrade rapidly in the gastrointestinal tract, BPC-157 demonstrates unusual resistance to enzymatic breakdown, making it a compelling subject for oral and systemic administration studies.

<h2>Mechanism of Action</h2>

The most extensively studied mechanisms of BPC-157 relate to its influence on the nitric oxide (NO) system and angiogenesis. Research published in peer-reviewed journals has shown that BPC-157 appears to upregulate endothelial nitric oxide synthase (eNOS) expression, promoting localized vasodilation and increasing blood flow to sites of injury. This angiogenic effect is thought to underlie much of its observed acceleration in wound healing — new capillary formation brings oxygen and nutrients to hypoxic tissue, a critical rate-limiting step in repair.

A second major area of investigation concerns BPC-157's interaction with the growth hormone receptor system. Several rodent studies have demonstrated that BPC-157 can modulate the expression of growth hormone receptors in tendon fibroblasts, potentially sensitizing these cells to endogenous GH signaling. The downstream effect appears to be enhanced collagen synthesis and tendon-to-bone integration, which has made it a popular subject in sports medicine research contexts. Separately, studies have documented upregulation of EGR-1 (early growth response protein 1), a transcription factor implicated in tendon repair gene expression.

<h2>Research Findings</h2>

A substantial body of preclinical literature — primarily from Croatian research groups including those affiliated with the University of Zagreb — has documented BPC-157's effects in rat and mouse models of tendon transection, Achilles tendon rupture, and colitis. In tendon studies, animals treated with BPC-157 consistently showed histologically superior repair tissue at two and four week endpoints compared to saline controls, with improved alignment of collagen fibrils and greater tensile strength on mechanical testing. In gut models, BPC-157 has been shown to accelerate the healing of gastric ulcers and reduce intestinal permeability in chemically-induced colitis models, which aligns with the hypothesis that its native function is gastroprotective.

It is important to note that the overwhelming majority of BPC-157 research is preclinical, conducted in rodent models. Human clinical trial data remains extremely limited. Translation from animal models to human outcomes is not guaranteed, and the mechanisms observed in vitro and in vivo in rodents may not operate identically in human physiology.

<h2>Protocol Considerations</h2>

In research settings, BPC-157 is typically administered via subcutaneous or intraperitoneal injection in rodent models, with doses ranging from 1 to 10 mcg/kg body weight in most published studies. Some researchers have also explored intragastric administration, taking advantage of the peptide's gastric stability. Reconstitution protocols typically use bacteriostatic water, and peptide stability post-reconstitution is an important variable that researchers should control for carefully. Storage at -20°C prior to reconstitution is standard practice in laboratory settings.

This article is for informational and research purposes only. Products are not intended for human consumption.`,
    category: 'research',
    coverImage: 'https://images.unsplash.com/photo-1532187863486-abf9dbad1b69?w=800&q=80',
    author: 'Dr. Research Team',
    publishedAt: '2026-05-20',
    readTime: 8,
  },
  {
    id: 'post-2',
    slug: 'peptide-purity-understanding-coa',
    title: 'Understanding Peptide Purity: How to Read a Certificate of Analysis',
    excerpt: 'Learn what HPLC purity percentages mean, what mass spectrometry confirms, and why third-party testing matters for research integrity.',
    content: `When purchasing peptides for research, purity is the most critical quality metric — yet it is also one of the most frequently misunderstood. A Certificate of Analysis (COA) is the primary document that communicates analytical test results for a given peptide batch. Understanding how to interpret a COA is fundamental to maintaining research integrity and ensuring that experimental results are attributable to the intended compound rather than to impurities or degradation products. This guide breaks down the key components of a peptide COA and what each data point actually tells you.

<h2>HPLC Purity: What the Percentage Really Means</h2>

High-Performance Liquid Chromatography (HPLC) is the gold-standard method for assessing peptide purity. In a reverse-phase HPLC analysis, the peptide sample is injected into a column and separated based on hydrophobicity. The resulting chromatogram displays peaks corresponding to each component in the sample, and the area under each peak is integrated. Purity is expressed as the percentage of the total peak area attributable to the target peptide.

A purity of 99% does not mean 99% of the sample by mass is the target peptide — it means 99% of the UV-absorbing material detected at 220nm is the target compound. This is an important distinction. Residual solvents, water, counterions (such as trifluoroacetate or acetate salts), and non-UV-absorbing impurities are not captured in this figure. A peptide reported at 99% HPLC purity may still contain significant amounts of trifluoroacetic acid (TFA), a common byproduct of Fmoc solid-phase peptide synthesis, which can be biologically active and interfere with cell-based assays.

<h2>Mass Spectrometry Confirmation</h2>

While HPLC tells you how pure the sample is, mass spectrometry (MS) tells you whether what you have is actually the correct compound. Electrospray ionization mass spectrometry (ESI-MS) or MALDI-TOF are typically used to confirm peptide identity by measuring the mass-to-charge ratio (m/z) of the molecule. A COA should report the theoretical molecular weight of the peptide alongside the observed m/z values from the mass spectrum. A match within acceptable tolerances (typically ±0.5 Da for smaller peptides) confirms correct synthesis and the absence of gross structural errors such as amino acid substitutions, deletions, or truncations.

Some manufacturers also include amino acid analysis (AAA), which provides quantitative confirmation of the amino acid composition. This is a more granular identity test and is particularly valuable for peptides where the mass alone might not distinguish between isomers or where post-translational modifications are relevant.

<h2>Why Third-Party Testing Matters</h2>

In-house testing by the manufacturer creates an obvious conflict of interest. Third-party testing — performed by an independent, accredited analytical laboratory with no financial stake in the outcome — provides a meaningful check on quality claims. Reputable third-party labs operate under ISO 17025 accreditation, which requires documented quality management systems, equipment calibration records, and proficiency testing. When evaluating a supplier's COA, look for the testing laboratory's name and, where possible, verify their accreditation status independently.

Batch-specific COAs are also important. A COA dated years before your purchase, or one that lacks a specific lot number traceable to the vial you received, offers no quality assurance for your actual sample. Each synthesis run can yield different impurity profiles depending on reagent quality, reaction conditions, and purification efficiency. Researchers should request and verify batch-specific documentation.

<h2>Protocol Considerations</h2>

When reviewing a COA for research use, check for: (1) HPLC purity above 98% for most research applications, with chromatogram trace included; (2) MS confirmation showing the correct molecular weight; (3) lot or batch number matching the supplied product; (4) testing laboratory name and date; and (5) counterion information if relevant to your assay system. If any of these elements are missing, contact the supplier before use.

This article is for informational and research purposes only. Products are not intended for human consumption.`,
    category: 'science',
    coverImage: 'https://images.unsplash.com/photo-1576671081837-49000212a370?w=800&q=80',
    author: 'Lab Quality Team',
    publishedAt: '2026-05-10',
    readTime: 6,
  },
  {
    id: 'post-3',
    slug: 'ipamorelin-cjc-1295-research-review',
    title: 'Ipamorelin + CJC-1295: A Review of Combined Protocol Research',
    excerpt: 'Exploring the published literature on combining selective GH secretagogues with GHRH analogues in preclinical and clinical research settings.',
    content: `The combination of Ipamorelin and CJC-1295 has become one of the most studied peptide pairings in the growth hormone secretagogue literature. The rationale for combining these two compounds rests on their complementary mechanisms: CJC-1295 acts on the GHRH receptor to prime the somatotrophs of the anterior pituitary, while Ipamorelin acts on the ghrelin receptor (GHS-R1a) to independently amplify GH pulse amplitude. When used together in research models, the result is a synergistic rather than merely additive increase in GH secretion — a profile that has made this combination an important tool in endocrinology research.

<h2>Mechanism of Action</h2>

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), a 44-amino acid hypothalamic neuropeptide that stimulates GH synthesis and release from pituitary somatotrophs. The native GHRH molecule has a short half-life in vivo due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) at position 2. CJC-1295 incorporates a substitution at this position along with a Drug Affinity Complex (DAC) — a lysine residue modified with a maleimidoproprionic acid group that enables covalent binding to circulating albumin. This albumin binding dramatically extends the half-life of CJC-1295 from minutes to several days, enabling sustained GHRH receptor stimulation across a research dosing window.

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that mimics ghrelin's action at the GHS-R1a receptor. Its key distinguishing feature in the research literature is its selectivity profile: unlike older secretagogues such as GHRP-2 or GHRP-6, Ipamorelin produces minimal increases in cortisol and prolactin at research-relevant doses. This selectivity makes it a cleaner research tool for isolating GH-specific effects without the confounding hormonal noise introduced by less selective compounds.

<h2>Research Findings</h2>

Preclinical studies using rodent and porcine models have consistently demonstrated that co-administration of a GHRH analogue with a GHS-R1a agonist produces GH pulse amplitudes substantially greater than either compound alone. The mechanism underlying this synergy appears to involve dual-pathway convergence on the pituitary somatotroph: GHRH receptor activation upregulates cAMP and stimulates GH gene transcription, while GHS-R1a activation increases intracellular calcium via a Gq/phospholipase C pathway, providing an additional secretory signal. The two pathways are not redundant — they engage distinct second messenger systems that converge at the level of secretory vesicle exocytosis.

Clinical research using CJC-1295 (with DAC) has demonstrated dose-dependent increases in mean 24-hour GH concentrations and IGF-1 levels in healthy adult subjects, with effects persisting for up to two weeks post-single-dose administration in some trials. Ipamorelin clinical data, while more limited, has shown favorable tolerability in Phase I/II studies. Combined protocols have been explored primarily in the context of age-related GH decline and body composition research, though large-scale randomized controlled trial data remain sparse.

<h2>Protocol Considerations</h2>

In preclinical research settings, Ipamorelin is typically administered at doses of 200-300 mcg/kg in rodent models, while CJC-1295 (with DAC) is used at lower frequencies due to its extended half-life. Researchers studying this combination should account for the distinct pharmacokinetic profiles when designing dosing schedules — the pulsatile nature of endogenous GH secretion and the potential for receptor desensitization with continuous stimulation are both variables that have been studied in the literature. Measurement endpoints in GH research should include both peak GH values and 24-hour secretion profiles via frequent sampling, as single time-point measurements can significantly underestimate the full secretory response.

This article is for informational and research purposes only. Products are not intended for human consumption.`,
    category: 'performance',
    coverImage: 'https://images.unsplash.com/photo-1534438327276-14e5300c3a48?w=800&q=80',
    author: 'Performance Research Desk',
    publishedAt: '2026-04-28',
    readTime: 10,
  },
]

export function getBlogPostBySlug(slug: string): BlogPost | undefined {
  return blogPosts.find((p) => p.slug === slug)
}
